Fig. 10

Jack A. Schalken. Jack A. Schalken trained as biochemist at Radboud University Medical Center, Nijmegen, the Netherlands, where he is Director of the urology research lab. His work focusses on translational research, with an emphasis on biomarkers and novel therapeutic targets such as epithelial–mesenchymal transition. His team’s research led to the clinical introduction of the first urine-based prostate cancer test (Progensa PCA3, 2006) and more recently to the SelectMdX test, which has been commercially available for clinical use since 2015. In 1996, he was appointed as full professor at the University of Utrecht (experimental oncology), and in 2001 as professor of experimental urology (Radboud University Medical Center). He has been awarded several scientific awards, most recently the Dominique Chopin award (2015) for his long-term contribution to the field